5 news items
Catheter Precision, Inc. (NYSE American: VTAK) Announces the First use of LockeT Outside of the United States
VTAK
11 Mar 24
was quick to observe that LockeT is not only simple in design, but simple to use and that it effectively creates hemostasis and provides additional benefits
Catheter Precision, Inc. (NYSE American:VTAK) Announces the First Use of VIVO With a Pediatric Patient in Turkey
VTAK
28 Feb 24
this continues to show the flexibility and many benefits of this innovative product."About VIVOCatheter Precision's VIVO
Catheter Precision, Inc. (NYS American:VTAK) Announces Attendance at the International Symposium on Left Atrial Appendage
VTAK
26 Feb 24
Atrial Appendage (LAA) and expands the audience to all cardiovascular physicians. LockeT's use in LAA procedures enables the benefits of our closure
Catheter Precision, Inc. Announces The Presentation Of The First Clinical Data On LockeT
VTAK
22 Feb 24
in achieving hemostasis but that it provides additional benefits of cost savings and same-day hospital discharge."The Western Afib symposium
Catheter Precision, Inc. Announces the Presentation of the First Clinical Data on LockeT
VTAK
22 Feb 24
benefits of cost savings and same-day hospital discharge."The Western Afib symposium is an internationally recognized meeting focused
- Prev
- 1
- Next